Jasper Therapeutics Announces CFO Resignation; Interim Finance Officers Appointed

What Happened Jasper Therapeutics (JSPR) filed an 8-K reporting that Chief Financial Officer Herb Cross submitted his resignation on September 23, 2026, effective October 9, 2026. On September 28, 2026 the board appointed President & CEO Jeet Mahal as interim Principal Financial Officer, Rick Ruiz as interim Principal Accounting Officer, and COO Matthew Ros as interim Corporate Secretary, each effective as of Mr. Cross’s resignation.

Key Details

• Resignation submitted: September 23, 2026; effective date: October 9, 2026.
• Interim appointments made: September 28, 2026 (Jeet Mahal as interim Principal Financial Officer; Rick Ruiz as interim Principal Accounting Officer; Matthew Ros as interim Corporate Secretary).
• Rick Ruiz: age 62, joined Jasper in 2024, former VP Finance at Atreca, prior roles at RoseRyan and KPMG; base salary of $364,000/year; eligible for equity awards under the Company’s equity plan and did not receive equity awards in connection with this promotion.
• The filing states there are no family relationships or special arrangements related to Mr. Ruiz’s appointment; biographical/compensation details for Mr. Mahal and Mr. Ros are in prior SEC filings referenced in the 8-K.

Why It Matters This 8-K signals a near-term change in Jasper’s finance leadership with the CFO leaving and key financial/accounting roles filled on an interim basis. Investors should note the company has named internal executives to cover principal financial and accounting officer responsibilities (including the CEO as interim Principal Financial Officer) and disclosed Ruiz’s salary and equity eligibility; the filing does not describe any departure-related payments or a timeline for a permanent replacement.